A recent study indicates that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Published data in a prominent medical journal points out that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these medications should be cognizant of the risk of fast weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to original mass in about one and a half years.
Weighing Therapies
The research, which looked at 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise generally experience a less rapid weight regain—around 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Experts suggest the mode of action of the injections explains the heightened regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the body to produce less of its endogenous hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Issue?
The NHS suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, given the likelihood of relapse, the therapy is often long-term.
This opinion is echoed by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
Users who have stopped the jabs describe a powerful return of cravings.
"I experienced a trigger that goes on and you become starving," described an individual.
The struggle is worsened if individuals have not established lasting dietary or behavioural modifications during therapy.
Widespread Interest
Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is more common among females than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while the jabs are effective agents for weight loss, they are not a standalone cure and lasting health benefits relies on combined behavioural management.
